Aldehyde-Trapping Compounds for Inflammatory Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory disorders often have limited effectiveness or are associated with adverse side effects due to their impact on the immune system and other physiological targets, failing to address specific aspects of the inflammatory response effectively.
Innovation Solution
Development of aldehyde-trapping compounds, such as those represented by formulas I, II, III, and IV, which react with aldehydes to prevent their interaction with biological molecules, thereby interfering with the inflammatory response in systemic and ocular inflammatory disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunosuppressants, cytokine inhibitors, or therapeutic antibodies are used to treat inflammatory disorders, then the inflammatory response is reduced, but adverse effects on the immune system and other physiological targets occur
Solution Approach 1:
The patent extracts and targets a specific component (aldehydes) of the inflammatory response pathway for treatment. By using aldehyde-trapping compounds that specifically react with and neutralize aldehydes, the invention selectively intervenes in the inflammatory cascade without broadly suppressing the immune system, thereby reducing inflammation while minimizing adverse effects on overall immune function and other physiological targets.
Solution Approach 2:
The patent introduces aldehyde-trapping compounds as intermediary agents that mediate between the inflammatory stimulus and the tissue damage outcome. These compounds act as chemical mediators that specifically capture aldehydes (such as 4-HNE and MDA) generated during inflammation, preventing them from causing further cellular damage while allowing the immune system to continue its normal protective functions.
2Reliability
If existing therapeutic agents are used to inhibit cytokine mediators or immune cells, then the inflammatory response is suppressed, but treatment effectiveness is limited for a significant percentage of patients
Solution Approach 1:
The patent converts the harmful aldehydes produced during inflammation into beneficial treatment targets. By designing compounds that specifically trap these toxic aldehyde byproducts (such as 4-HNE and MDA), the invention transforms the inflammatory process's harmful outputs into the basis for selective therapeutic intervention, providing an alternative mechanism that can benefit patients who do not respond to conventional cytokine or immune cell-targeted therapies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The aldehyde-trapping compounds effectively treat a wide range of inflammatory disorders by reducing inflammation and minimizing side effects, as demonstrated by their use in conditions like non-alcoholic fatty liver disease, inflammatory bowel disease, and ocular inflammatory disorders, with improved safety profiles compared to existing therapies.
Implementation Method 1
compounds that are capable of reacting with aldehydes for the treatment of certain inflammatory disorders
Data Source
AI summary
The present disclosure provides compounds and methods of use thereof for treating inflammatory diseases or disorders.